Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma

Melanoma Research

Volumn 18, Issue 6, 2008, Pages 412-419

  Bolander, Åsa ^a   Agnarsdóttir, Margrét ^b   Wagenius, Gunnar ^a   Strömberg, Sara ^b   Pontén, Fredrik ^b   Ekman, Simon ^a   Brattström, Daniel ^c   Larsson, Anders ^a   Einarsson, Roland ^d   Ullenhag, Gustav ^a   Hesselius, Patrik ^a   Bergqvist, Michael ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Fujirebio Diagnostics Inc   (Sweden)

Author keywords

Immunohistochemistry; Malignant melanoma; Prognosis; S100; S100A1B; S100A4; S100BB; Serum marker; Survival

Indexed keywords

CALVASCULIN; PROTEIN S 100; PROTEIN S100A1B; PROTEIN S100BB; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SEROLOGY; TISSUE MICROARRAY;

FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; S100 PROTEINS; SEROLOGIC TESTS; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 56849100767     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328315c690     Document Type: Article

References (33)

1. Gaynor R, Herschman HR, Irie R. S100 protein: a marker for human malignant melanomas? Lancet 1981; 1:869-871.
2. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004; 37:512-518.
3. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21:134-140.
4. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002; 7:d1356-d1368.
5. Marenholz I, Lovering RC, Heizmann CW. An update of the S100 nomenclature. Biochim Biophys Acta 2006; 1763:1282-1283.
6. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 1980; 286:400-401.
7. Martenson ED, Nilsson B, von Schoultz E, Mansson Brahme E, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19:824-831.
8. Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krahn G. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. J Am Acad Dermatol 1999; 41:962-969.
9. Seregni E, Massaron S, Martinetti A, Illeni MT, Rovini D, et al. S100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 1998; 5:601-604.
10. Banfalvi T, Gilde K, Boldizsar M, Kremmer T, Otto S. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol Oncol Res 1999; 5:218-222.
11. Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 1998; 77:2210-2214.
12. Curry BJ, Farrelly M, Hersey P. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma. Melanoma Res 1999; 9:557-567.
13. Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, et al. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol 2007; 28:264-272.
14. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17:1891-1896.
15. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56:338-344.
16. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, et al. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 1996; 3:558-563.
17. Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005; 41:386-392.
18. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999; 9:155-161.
19. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998; 138:426-430.
20. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology 1997; 194:208-212.
21. Buer J, Probst M, Franzke A, Duensing S, Haindl J, et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997; 75:1373-1376.
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-847.
23. Kampf C, Wester K, Björling E, Uhlen M, Ponten F. Antibody-based tissue profiling as a tool for clinical proteomics. Clin Proteom 2004; 1:285-299.
24. Ghanem G, Loir B, Morandini R, Sales F, Lienard D, et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer 2001; 94:586-590.
25. Abraha HD, Fuller LC, Du Vivier AWP, Higgins EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997; 137:381-385.
26. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O. Differential expression patterns of 〈I〉S100a2, S100a4〈/I〉 and 〈I〉S100a6〈/I〉 during progression of human malignant melanoma. Int J Cancer 1997; 74:464-469.
27. Cui JF, Liu YK, Zhang LJ, Shen HL, Song HY, et al. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 2006; 6:5953-5961.
28. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004; 54:131-149; quiz 182-4.
29. Jury CS, McAllister EJ, Mackie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000; 143:269-274.
30. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R. Detection of melanoma relapse: First comparative analysis on imaging techniques versus S100 protein. Dermatology 2006; 213:187-191.
31. Acland K, Evans AV, Abraha H, Healy CM, Roblin P, et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 2002; 146:832-835.
32. Andersen K, Nesland JM, Holm RF, Iorenes VA, Fodstad O, Maelandsmo GM. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 2004; 17:990-997.
33. Ikoma N, Yamazaki H, Abe Y, Oida Y, Ohnishi Y, et al. S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model. Oncol Rep 2005; 14:633-637.